Jérôme Tilly

Stallergenes SA is an international biopharmaceutical company, which engages in the manufacture and sale of pharmaceutical products for the treatment of allergy-related respiratory diseases. The company operates through the Allergen Immunotherapy segment, which provides products and services for the desensitization of allergy-related respiratory conditions. Its products include a range of sublingual route and subcutaneous route products for the treatment of respiratory diseases such as rhino-conjunctivitis, rhinitis, and allergic asthma. Stallergenes was founded in 1962 and is headquartered in Antony, France.

Stallergenes Greer Ltd. is a healthcare company, which engages in the development and commercialization of allergy immunotherapy products and services. Its products include sublingual products, subcutaneous products, and veterinary products. The company was founded on December 6, 2013 and headquartered in London, the United Kingdom.